Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

First Posted Date
2016-12-01
Last Posted Date
2016-12-20
Lead Sponsor
Meshalkin Research Institute of Pathology of Circulation
Target Recruit Count
200
Registration Number
NCT02979561
Locations
🇷🇺

Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

First Posted Date
2016-10-24
Last Posted Date
2020-12-29
Lead Sponsor
Christopher Granger, MD
Target Recruit Count
154
Registration Number
NCT02942407
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

🇺🇸

Nephrology & Hypertension Associates, Tupelo, Mississippi, United States

🇺🇸

Nuren Medical and Research Center, Miami, Florida, United States

and more 51 locations

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

First Posted Date
2016-10-18
Last Posted Date
2020-11-10
Lead Sponsor
University of Pavia
Target Recruit Count
300
Registration Number
NCT02935855
Locations
🇮🇹

IRCCS Policlinico San Matteo, Pavia, Italy

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2016-09-23
Last Posted Date
2019-08-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
120
Registration Number
NCT02913326
Locations
🇮🇳

Caritas Hospital, Kottayam, India

🇮🇳

Mazumdar Shaw Medical centre, Bangalore, India

🇮🇳

Nizam's Institute of Medical Sciences, Hyderabad, India

and more 33 locations

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

First Posted Date
2016-09-05
Last Posted Date
2021-01-22
Lead Sponsor
Sanford Health
Target Recruit Count
56
Registration Number
NCT02889562
Locations
🇺🇸

Sanford Health, Fargo, North Dakota, United States

TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV

First Posted Date
2016-08-03
Last Posted Date
2016-08-03
Lead Sponsor
Zaibo Jiang
Target Recruit Count
100
Registration Number
NCT02853526
Locations
🇨🇳

Department of Radiology, Guangzhou, Guangdong, China

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

First Posted Date
2016-07-19
Last Posted Date
2022-06-27
Lead Sponsor
Abbott Medical Devices
Target Recruit Count
72
Registration Number
NCT02836652
Locations
🇺🇸

Baptist Memorial Hospital, Memphis, Tennessee, United States

🇺🇸

Westchester Medical Center, Valhalla, New York, United States

🇺🇸

Temple University Hospital, Philadelphia, Pennsylvania, United States

and more 32 locations

Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement

First Posted Date
2016-06-23
Last Posted Date
2024-12-11
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
20000
Registration Number
NCT02810704
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

UCLA, Los Angeles, California, United States

and more 28 locations

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

First Posted Date
2016-05-26
Last Posted Date
2016-05-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13
Registration Number
NCT02783040
Locations
🇩🇪

1346.22.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2024. All Rights Reserved by MedPath